Higgs Boson Decay into Hadronic Jets

The remarkable agreement of electroweak data with standard model (SM) predictions motivates the study of extensions of the SM in which the Higgs boson is light and couples in a standard way to the weak gauge bosons. Postulated new light particles should have small couplings to the gauge bosons. Within this context it is natural to assume that the branching fractions of the light SM-like Higgs boson mimic those in the standard model. This assumption may be unwarranted, however, if there are non-standard light particles coupled weakly to the gauge bosons but strongly to the Higgs field. In particular, the Higgs boson may effectively decay into hadronic jets, possibly without important bottom or charm flavor content. As an example, we present a simple extension of the SM, in which the predominant decay of the Higgs boson occurs into a pair of light bottom squarks that, in turn, manifest themselves as hadronic jets. Discovery of the Higgs boson remains possible at an electron-positron linear collider, but prospects at hadron colliders are diminished substantially.Comment: 30 pages, 7 figure

From the LHC to Future Colliders

Discoveries at the LHC will soon set the physics agenda for future colliders. This report of a CERN Theory Institute includes the summaries of Working Groups that reviewed the physics goals and prospects of LHC running with 10 to 300/fb of integrated luminosity, of the proposed sLHC luminosity upgrade, of the ILC, of CLIC, of the LHeC and of a muon collider. The four Working Groups considered possible scenarios for the first 10/fb of data at the LHC in which (i) a state with properties that are compatible with a Higgs boson is discovered, (ii) no such state is discovered either because the Higgs properties are such that it is difficult to detect or because no Higgs boson exists, (iii) a missing-energy signal beyond the Standard Model is discovered as in some supersymmetric models, and (iv) some other exotic signature of new physics is discovered. In the contexts of these scenarios, the Working Groups reviewed the capabilities of the future colliders to study in more detail whatever new physics may be discovered by the LHC. Their reports provide the particle physics community with some tools for reviewing the scientific priorities for future colliders after the LHC produces its first harvest of new physics from multi-TeV collisions.Comment: 98 pages, CERN Theory Institute Summary Repor

Jets and QCD: A Historical Review of the Discovery of the Quark and Gluon Jets and its Impact on QCD

The observation of quark and gluon jets has played a crucial role in establishing Quantum Chromodynamics [QCD] as the theory of the strong interactions within the Standard Model of particle physics. The jets, narrowly collimated bundles of hadrons, reflect configurations of quarks and gluons at short distances. Thus, by analysing energy and angular distributions of the jets experimentally, the properties of the basic constituents of matter and the strong forces acting between them can be explored. In this review, which is primarily a description of the discovery of the quark and gluon jets and the impact of their observation on Quantum Chromodynamics, we elaborate, in particular, the role of the gluons as the carriers of the strong force. Focusing on these basic points, jets in e+e− collisions will be in the foreground of the discussion and we will concentrate on the theory that was contemporary with the relevant experiments at the electron-positron colliders. In addition we will delineate the role of jets as tools for exploring other particle aspects in ep and \hbox{$pp/p\bar{p}$} collisions  −  quark and gluon densities in protons, measurements of the QCD coupling, fundamental 2-2 quark/gluon scattering processes, but also the impact of jet decays of top quarks, and W ± , Z bosons on the electroweak sector. The presentation to a large extent is formulated in a non-technical language with the intent to recall the significant steps historically and convey the significance of this field also to communities beyond high energy physics

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1.91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), respectively. There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the aspirin group. INTERPRETATION: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin